These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 30294716)
1. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Fu Y; Ho M Antib Ther; 2018 Sep; 1(2):33-43. PubMed ID: 30294716 [TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads. Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862 [TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates: Recent advances in payloads. Wang Z; Li H; Gou L; Li W; Wang Y Acta Pharm Sin B; 2023 Oct; 13(10):4025-4059. PubMed ID: 37799390 [TBL] [Abstract][Full Text] [Related]
4. Advances with antibody-drug conjugates in breast cancer treatment. Abdus Subhan M; Torchilin VP Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933 [TBL] [Abstract][Full Text] [Related]
5. Stepping forward in antibody-drug conjugate development. Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334 [TBL] [Abstract][Full Text] [Related]
6. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Peng H Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745 [TBL] [Abstract][Full Text] [Related]
7. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions. Li C; Shi K; Zhao S; Liu J; Zhai Q; Hou X; Xu J; Wang X; Liu J; Wu X; Fan W Pharmacol Res; 2024 Sep; 207():107341. PubMed ID: 39134188 [TBL] [Abstract][Full Text] [Related]
8. Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer. Koukoutzeli C; Trapani D; Ascione L; Kotteas E; Marra A; Criscitiello C; Curigliano G Clin Med Insights Oncol; 2024; 18():11795549241260418. PubMed ID: 38894701 [TBL] [Abstract][Full Text] [Related]
9. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy. Fatima SW; Khare SK J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604 [TBL] [Abstract][Full Text] [Related]
10. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Hong Y; Nam SM; Moon A Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356 [TBL] [Abstract][Full Text] [Related]
11. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads. Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791 [TBL] [Abstract][Full Text] [Related]
12. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038 [TBL] [Abstract][Full Text] [Related]
13. The target invites a foe: antibody-drug conjugates in gynecologic oncology. Campos MP; Konecny GE Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302 [TBL] [Abstract][Full Text] [Related]
14. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer. Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496 [TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. Theocharopoulos C; Lialios PP; Samarkos M; Gogas H; Ziogas DC Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696218 [TBL] [Abstract][Full Text] [Related]
16. Update of antibody-drug conjugates for hematological malignancies. Sun W; Hu S; Wang X Curr Opin Oncol; 2024 Sep; 36(5):430-436. PubMed ID: 39007226 [TBL] [Abstract][Full Text] [Related]
17. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates. Schwach J; Abdellatif M; Stengl A Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167 [TBL] [Abstract][Full Text] [Related]
18. Advances and Limitations of Antibody Drug Conjugates for Cancer. Mckertish CM; Kayser V Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440076 [TBL] [Abstract][Full Text] [Related]